C ell death after cerebral ischemic insult can be induced in 3 ways: (1) by excitation (excitotoxicity), (2) by oxidative stress with free radicals, and (3) by apoptosis. 1 When the brain fails to generate sufficient ATP and this results in energy failure, ionic gradients are lost. 1 At this stage, glutamate is released, reuptake processes are impaired, and glutamate binds to its postsynaptic receptors and promotes excitotoxic processes as well as a radical-induced apoptotic course. 1 Thus, a number of NMDA receptor antagonists have been developed and used for the treatment of neurological diseases in patients, but all have failed clinical trials because of intolerable side effects or a lack of medical efficacy. 2 Glutamate transporters play a crucial role in removing glutamate released from synaptic clefts. 3 Released glutamate is taken up by glial cells and metabolized to glutamine, which is then transported back into neurons, converted to glutamate, and sequestered into synaptic vesicles by vesicular glutamate transporters. 4 In addition, it has been demonstrated that glutamate transporter-1 (GLT-1; EAAT2) and glutamate/ aspartate transporter, both glial isoforms, are the predominant means of functional glutamate transport, and that they are essential for maintaining low extracellular glutamate, preventing chronic glutamate neurotoxicity, 3, 4, 5 and for neuronal survival in the ischemic penumbra. 5, 6 Recently and unexpectedly, it was postulated that ␤-lactam antibiotics are potent stimulators of GLT-1 expression. 7 Moreover, ceftriaxone (CTX), which efficiently penetrates the blood-brain barrier, was found to be neuroprotective in vitro when administered under oxygen-glucose deprived conditions, and in an in vivo mouse model of amyotropic lateral sclerosis. 7 Thus, based on the findings of this study, we investigated whether GLT-1 upregulation induced by CTX can induce ischemic tolerance and improve functional recovery in experimental focal cerebral ischemia. To determine the optimal time required for CTX to induce maximal GLT upregulation, in a pilot study we injected CTX (200 mg/kg, IP) for up to 7 days preoperatively (nϭ18). CTX dose and treatment schedules were chosen based on the findings of a previous study. 7 For GLT-1 RT-PCR and western blotting experiments, rats were euthanized at 6 hours, and at 1, 2, 3, 5, and 7 days after the first CTX injection.
Materials and Methods

Animal Model and Experimental Protocol
Based on this pilot study, we injected CTX (200 mg/kg per day, in PBS; CJ Pharmaceuticals) or PBS (vehicle) into rats intraperitoneally for 5 days before ischemia (total 5 days). The rats for behavioral tests were also injected for additional 3 days postischemia (total 8 days). For comparison purposes, we included the CTX-post reperfusion group, in which daily CTX was started at 30 minutes after the ischemic insult. The lower doses of CTX (20 mg/kg per day, 100 mg/kg per day, nϭ9 respectively) were also tested to evaluate dosage-effects. All other injections of CTX were at 200 mg/kg per day. To verify the causal role of GLT-1 upregulation in neuroprotection, some rats were injected once with the selective GLT-1 inhibitor, dihydrokainate (DHK, 10 mg/kg, IP; Tocris), at 30 minutes before the ischemia induction ( CTX DHK group, vehicle DHK group). The glial transporter GLT1 is inhibited potently by DHK. 8 Transient focal cerebral ischemia was induced by the intraluminal occlusion of the middle cerebral artery (MCAo) using a thread for 90 minutes in both groups, as described elsewhere. 9 For comparison, permanent focal cerebral ischemia was induced by leaving the intraluminal filament in position. Physiological parameters, including mean arterial blood pressures, blood gases, and glucose concentrations, were measured throughout surgery. Rectal temperatures were maintained throughout surgery at 37Ϯ0.5°C using a thermistorcontrolled heated blanket. Animals were maintained in separate cages at room temperature (25°C) with free access to food and water, under a 12-hour light-dark cycle. Modified limb placing tests (MLPT) were performed 1 day before and 1 day after ischemia, and weekly thereafter (nϭ6 per group) for 5 weeks, as described previously. 10, 11 MLPT results were used to assess the sensorimotor integration of forelimbs and hindlimbs by verifying their responses to tactile and proprioceptive stimuli.
Infarct Volume Measurement
In order to compare infarct sizes in the ischemia-treated groups, we measured infarct volumes (at 24 hours postischemia; nϭ9 per group) using 2,3,5-triphenyltetrazolium chloride (TTC; Sigma) staining, as described elsewhere. 10 Infarcted and total hemispheric areas of sections were traced from slices taken at 1-mm intervals and measured using an image analysis system (Image-Pro Plus; Media Cybernetics). Two investigators (K.C. and S.T.L.) unaware of study group identities measured infarct sizes using a computerized image analyzer (Bio-Rad). To compensate for the effect of brain edema, corrected infarct volumes were calculated as previously described using: Corrected infarct areaϭMeasured infarct areaϫ{1Ϫ[(Ipsilateral hemisphere areaϪContralateral hemisphere area)/Contralateral hemisphere]}. 12 Infarct volumes were expressed as percentages of total hemispheric volumes.
GLT-1 Protein Expression
GLT-1 western blotting was performed as previously described, 13 using anti-GLT-1 antibody (1:200; Santa Cruz) and secondary antibody conjugated with horseradish peroxidase. Anti-␤-actin antibody (Santa Cruz) was used as the control. Blots were developed by enhanced chemiluminescence (Pierce), digitally scanned (GS-700; Bio-Rad), and analyzed (Molecular Analyst; Bio-Rad). Relative optical densities were obtained by comparing measured values with the mean values of normal rats.
RT-PCR for GLT-1 and Inflammatory Mediators
Twenty-four hours after the induction of ischemia, rats were euthanized by decapitation, and brains were immediately extracted (nϭ4 in each group). RT-PCR for GLT-1, interleukin-6, Fas, FasL, tumor necrosis factor (TNF)-␣, and MMP-2/9 were conducted using a previously described method in ischemic hemispheres (for detailed primer sets see supplemental Table I , available online at http:// stroke.ahajournals.org). 11 mRNA expression levels were normalized versus GAPDH, and relative optical densities were determined by comparing mean measured values with the mean value of the vehicle Reperfusion group.
Measurement of Caspase Activities
Caspase activities were determined using ELISA kits (Caspase-3: Promega; Caspase-8: BD Biosciences; Caspase-9: Chemicon) in ischemic hemispheres, 24 hours after the induction of MCAo (nϭ4 per group), as previously described. 14 Fluorescent intensities were measured using a plate reader (FL600; Bio-Tek; excitation wavelength: 380 nm; emission wavelength: 460 nm).
Statistical Analysis
All values are expressed as meanϮSD. The analysis was conducted using repeated measures of analysis of variance and the unpaired Student t test, if normally distributed (Kolmogorov-Smirov test; PϾ0.05). Alternatively, we used the Mann-Whitney U tests, or specified the test used. A 2-tailed P value of Ͻ0.05 was considered to be significant.
Results
CTX Treatment Upregulated GLT-1 Expression In Vivo
To examine GLT-1 temporal expression profiles in vivo, as a pilot study, we injected CTX daily (200 mg/kg per day, up to 7 days), and euthanized rats at various timepoints ( CTX normal group, nϭ18). GLT-1 mRNA expressions in brain increased after CTX administration and peaked after 3 days (1.7-fold), whereas GLT-1 protein levels peaked after 5 days of treatment (Figure 1 ). Based on this result, we decided to administer CTX for 5 days before the ischemic insult.
CTX Treatment Enhanced Functional Recovery
Physiological parameters, including mean arterial blood pressure, blood gases, serum glucose, and body temperature did not differ significantly between the 2 experimental groups ( vehicle reperfusion group and CTX reperfusion group) before, during, or 30 minutes after MCAo (ANOVA; supplemental Figure 2a) . Moreover, the CTX reperfusion group continued to recover, and MLPT differences between the 2 groups remained significant until at least 5 weeks after MCAo induction (PϽ0.01; t test). At week 5, the CTX reperfusion group had the MLPT score of Ͻ1.
CTX Pretreatment Reduced Infarct Volume
The CTX reperfusion group exhibited a reduced infarct volume (by 58%) versus the vehicle reperfusion group, at 24 hours postischemia (Figure 2b) Figure 2b ). Dihydrokainate injection without CTX-pretreatment ( vehicle DHK group) showed no significant difference in mean infarct volume 
CTX Treatment Reduced Caspase-9 Activity and Downregulated Proinflammatory Cytokines
Caspase-9 activity in the ischemic hemisphere was significantly reduced in the CTX reperfusion group versus the vehicle reperfusion group (62% decrease; PϽ0.01; Figure 3a) . However, the activities of caspases-8 and 3 were not changed by ceftriaxone treatment. We measured the mRNA expressions of cytokine-related genes, namely, TNF-␣, Fas, FasL and interleukin-6, and relative optical density analysis revealed that the CTX reperfusion group showed an 86% decrease in the levels of TNF-␣, and a 78% reduction in FasL mRNA levels versus the vehicle reperfusion group (PϽ0.01; Figure 3b and 3c). The levels of Fas and interleukin-6 mRNA were unchanged by CTX pretreatment. In addition, we analyzed the mRNA levels of the proteolytic enzymes (MMP-2 and MMP-9), and found that MMP-2 levels were unchanged, but that MMP-9 mRNA levels were reduced by 95% attributable to CTX pretreatment.
Discussion
In this study, we investigated the neuroprotective effect of GLT-1 upregulation during cerebral ischemia. CTX treatment was found to upregulate GLT-1 and to reduce infarct volumes in both transient and permanent cerebral ischemic models. Moreover, the inhibition of GLT-1 ameliorated the ischemic tolerance induced by CTX, and post-treatment with CTX at 30 minutes after ischemia failed to reduce infarct volume. These results suggest that the mechanism of neuroprotection is based on GLT-1 upregulation. In addition, reduced infarct volumes corresponded with improved and sustained neurological outcomes.
Extracellular glutamate concentrations showed transient elevations immediately (within 30 minutes) after an ischemic insult. 15 In a reperfusion model, this initial peak in glutamate levels was followed by 2 secondary elevations in glutamate at 50 minutes and 90 minutes after initiating reperfusion. 15 However, although glutamate-induced excitotoxicity is a crucial component of the initial ischemic insult, all tested antiglutamatergic drugs have failed in clinical trials. 2 One of the reasons for this failure might be the rapid and early increase in extracellular glutamate after ischemia, whereas drugs are administered several hours after the event. In the present study, CTX had already increased GLT-1 expression at the time of ischemia, and as such GLT-1 was available to attenuate excitotoxicity. In addition, glutamate release occurs more than once during the early reperfusion phase. 15 Thus, increased GLT-1 levels by CTX explain the enhanced neuroprotection (reduced infarct volume) observed in the CTX reperfusion group versus the CTX permanent group. There are at least 5 subtypes of glutamate transporters in the mammalian central nervous system. 16 GLT-1 is the predominant subtype and is responsible for the bulk of glutamate reuptake. 16 Moreover, the infusion of GLT-1 antisense led to a significant increase in infarct volumes after reperfusion in a rat ischemia model and a severe neurological deterioration. 17 On the other hand, the neuronal glutamate transporter, EAAC-1 antisense, did not influence ischemic injury. 17 Ischemic preconditioning depends on the expression of astrocytic GLT-1 and the level of its reverse operation. 18 Because glutamate transporters are dynamic proteins that can release or uptake glutamate, their function depends on their regional and cellular localizations, cerebral energy statuses, and the durations and types of neuronal insults. It is known that the reversal of GLT-1 contributes to ischemia-induced increases in excitatory amino acids in the ischemic core. 19 GLT-1 upregulation by CTX might worsen extracellular excitatory amino acids levels in situations of transporter reversal. However, excitatory amino acids release through reversed GLT-1 may not be significant in the ischemic penumbra because dihydrokainate did not reduce excitatory amino acids release in mild ischemic areas, suggesting a diminished transporter reversal role in the penumbra. 19 The normal function of GLT-1, rather than the reversed operation of GLT-1 transporter, seems to dominate in the ischemic penumbra. Our study also suggests that the enhanced expression of GLT-1 exerts a beneficial effect on the ischemic brain.
The relation between GLT-1 and inflammation is not fully understood. Reactive astrocytes express inflammatory makers, such as the inducible forms of nitric oxide synthase and cyclooxygenase, and secrete proapoptotic mediators, such as FasL, and downregulate GLT-1. 20 -22 Meanwhile, TNF-␣ plays a facilitatory role in glutamate excitotoxicity, both directly and indirectly, by inhibiting glial glutamate transporters on astrocytes. TNF-␣ also has direct effects on glutamate transmission, such as by increasing the expression of AMPA receptors on synapses. 23 In addition, we previously presented evidence that NMDA blocker can reduce endogenous tissue plasminogen activator (tPA) and MMP-9 expressions. 11 In the present study, we found that GLT-1 upregulation reduced the expressions of TNF-␣, FasL, and MMP-9. Accordingly, we suggest that the clearance of extracellular glutamate by upregulated GLT-1 might synergistically reduce inflammation and apoptosis. However, caspase-3 levels were not reduced by CTX in the present study, and CTX might influence other cell death pathway such as calpain, which is one of the major cell-death effecters induced by glutamate excitotoxicity in cerebral ischemia. 24 This topic requires further investigations.
The clinical implications of CTX-pretreatment require further discussion. In the amyotropic lateral sclerosis model, the chronic administration of CTX delayed neuronal loss and muscle strength, and increased mouse survival. 7 However, it needs time to upregulate GLT-1 and therefore is difficult to apply to acute neuroprotection. Thus, instead of using CTX CTX reperfusion group showed a reduction of caspase-9 activity (A). However, caspase-3 and -8 activities were unchanged. FasL, TNF-␣, and MMP-9 mRNA levels were also reduced in 
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for acute therapy, it may be applied to induce ischemic tolerance in situations, such as carotid endarterectomy, cardiopulmonary bypass surgery, or in those with a high perioperative risk of ischemic stroke. For bacterial infections, the usual adult daily dose of CTX is 1 to 2 g given once daily in adults, and 50 to 100 mg/kg once daily in pediatric patients. Thus, the dose used in this study (200 mg/kg per day) is relatively high as compared with clinical practice. Although ceftriaxone has a good tolerability profile, high doses of CTX can cause adverse effects, which include diarrhea, nausea, vomiting, candidiasis, and sometimes reversible biliary pseudolithiasis. 25 However, it has been shown that the EC50 required to increase GLT1 expression by ceftriaxone is 3.5 mol/L, 7 which is comparable to the known central nervous system levels attained during therapy for meningitis (0.3 to 6 mol/L). 26 Thus, normal antimicrobial CTX doses are likely to be sufficient to induce GLT-1 upregulation in humans.
In summary, we present evidence that ceftriaxone induces ischemic tolerance in focal cerebral ischemia, which is mediated by GLT-1 upregulation. CTX-induced GLT-1 upregulation might provide a novel antiglutaminergic approach in ischemic stroke. 
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